NCT05406778 is a NA clinical trial of SPARK Test in Alzheimer Disease, sponsored by Spark Neuro Inc..

Who is sponsoring NCT05406778?

NCT05406778 is sponsored by Spark Neuro Inc..

What drugs are being tested in NCT05406778?

Interventions in NCT05406778: SPARK Test.

What condition does NCT05406778 study?

NCT05406778 studies Alzheimer Disease, Cognitive Impairment.

Is NCT05406778 still recruiting?

NCT05406778 is currently completed. Last updated 14 August 2025.

Last reviewed 2025-08-14 · How we verify

NCT05406778

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The REMIND Study- SPARK Neuro Software Study

Completed NA Last updated 14 August 2025

What this trial tests

NA trial testing SPARK Test in Alzheimer Disease in 185 participants. Completed in 19 January 2024.

Timeline

18 May 2022

Primary endpoint
24 August 2023

19 January 2024

Quick facts

Lead sponsor	Spark Neuro Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	185
Start date	18 May 2022
Primary completion	24 August 2023
Estimated completion	19 January 2024
Sites	7 locations across United States

Drugs / interventions tested

SPARK Test

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Spark Neuro Inc.

Who can join

Adults 55 to 85, any sex, with Alzheimer Disease or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Spark Neuro Inc. trials

Trials by the same sponsor.

NCT06809725 — Software Validation Study-Cognitive Status Indicator · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05406778 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spark Neuro Inc.
Last refreshed: 14 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05406778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing